文献类型：期刊文献

英文题名：The Prognostic Value of lncRNA MCM3AP-AS1 on Clinical Outcomes in Various Cancers: A Meta- and Bioinformatics Analysis

作者：Fu, Liangyin[1,2,3,4];Zhang, Guangming[1,2,3,4];Wang, Yongfeng[1,2,3,4];Lu, Tingting[4];Liu, Bin[4];Jiao, Yajun[4];Ma, Haizhong[4];Ma, Shixun[4];Yang, Kehu[5];Cai, Hui[1,2,3,4,6]

第一作者：Fu, Liangyin

通信作者：Cai, H[1];Cai, H[2];Cai, H[3];Cai, H[4];Cai, H[5]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou 730000, Peoples R China;[2]Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou 730000, Peoples R China;[3]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou 730000, Peoples R China;[4]Gansu Prov Hosp, Lanzhou 730000, Peoples R China;[5]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou 730000, Peoples R China;[6]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, Lanzhou 730000, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Gen Surg Clin Med Ctr, Lanzhou 730000, Peoples R China;[3]corresponding author), Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou 730000, Peoples R China;[4]corresponding author), Gansu Prov Hosp, Lanzhou 730000, Peoples R China;[5]corresponding author), Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, Lanzhou 730000, Peoples R China.|[10735]甘肃中医药大学;

年份：2022

卷号：2022

外文期刊名：DISEASE MARKERS

收录：;Scopus(收录号：2-s2.0-85133295658);WOS:【SCI-EXPANDED(收录号:WOS:000886353100012)】；

基金：We would like to thank Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province and The DaVinci Surgery System Database (DSSD, http://www.davincisurgerydatabase.com/) for their contributions. This study was supported by grants from the Central to Guide Local Scientific and Technological Development (ZYYDDFFZZJ-1); Key talent project of Gansu Province of the Organization Department of Gansu Provincial Party Committee (2020RCXM076); Key Laboratory of gastrointestinal cancer diagnosis and treatment of National Health Commission (2019PT320005); Gansu Provincial Youth Science and Technology Fund Program (21JR7RA642); Gansu Key Laboratory of Molecular Diag-nosis and Precision Treatment of Surgical Tumors (18JR2RA033); Lanzhou Talent Innovation and Entrepreneurship Project (2016-RC-56); and the major project of Department of Education of Gansu Province, "the reform and practical exploration of talent cultivation mode of "school-institute co-construction": Postgraduate "Innovation Fund" project (LCCX2021013).

语种：英文

摘要：Background. MCM3AP antisense RNA 1 (MCM3AP-AS1) is a newly identified potential tumor biomarker. Nevertheless, the prognostic value of MCM3AP-AS1 in cancer has been inconsistent in the available studies. We performed this meta-analysis to identify the prognostic role of MCM3AP-AS1 in various cancers. Methods. We searched PubMed, Web of Science, EMBASE, and the Cochrane Library databases to screen relevant studies. Hazard ratios (HR) or odds ratios (OR) and corresponding 95% confidence intervals (CI) were used to evaluate the relationship between aberrant MCM3AP-AS1 expression and survival and clinicopathological features (CFS) of cancer patients. A meta-analysis was performed using STATA 12.0 software. Additionally, results were validated by an online database based on The Cancer Genome Atlas (TCGA). Subsequently, we analyzed the MCM3AP-AS1-related genes and molecular mechanisms based on the MEM database. Results. Our results showed that overexpression of MCM3AP-AS1 was related to poor overall survival (OS) (HR=2.00, 95% CI, 1.52-2.64, P < 0.001) and relapse-free survival (RFS) (HR=3.28, 95% CI 1.56-6.88, P=0.002). In addition, MCM3AP-AS1 overexpression was associated with TNM stage, differentiation grade, and lymph node metastasis, but not significantly with age, gender, and tumor size. In addition, MCM3AP-AS1 overexpression was verified by the GEPIA online database to be associated with poorer survival. The further functional investigation suggested that MCM3AP-AS1 may be involved in several cancer-related pathways. Conclusions. The overexpression of MCM3AP-AS1 was related to poor survival and CFS. MCM3AP-AS1 may be considered a novel prognostic marker and therapeutic target in various cancers.